Signals, Powered By EquityPandit
Zydus Cadila has received final approval to market two drugs, from the US health regulator.
The company stated that, it has received approval to market Methylprednisolone tablets USP in the strengths of 4 mg, 8 mg, 16 mg and 32 mg and Cinacalcet hydrochloride tablets in the strengths of 30 mg, 60 mg and 90 mg, in the American Market.
Methylprednisolone tablets will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad, and is used to treat various conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin, kidney, intestinal, lung diseases and immune system disorders.
Further, Cinacalcet hydrochloride tablets will be manufactured at the group’s formulations manufacturing facility at SEZ Ahmedabad, and it is suggested for treatment of high blood calcium in patients with cancer of parathyroid glands and for the treatment of high blood parathyroid hormone levels seen in patients with chronic kidney disease on dialysis.
